Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.?
| Revenue (Most Recent Fiscal Year) | $57.88M |
| Net Income (Most Recent Fiscal Year) | $-519.02M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 17.76 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.37 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -774.94% |
| Net Margin (Trailing 12 Months) | -774.94% |
| Return on Equity (Trailing 12 Months) | -57.01% |
| Return on Assets (Trailing 12 Months) | -44.39% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.21 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.21 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.92 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.92 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.27 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 107.35M |
| Free Float | 104.02M |
| Market Capitalization | $1.02B |
| Average Volume (Last 20 Days) | 11.06M |
| Beta (Past 60 Months) | 2.45 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 88.77% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |